Nasdaq

iMDx Announces Positive Study Results Showing Equivalence of GraftAssureIQ with NGS dd-cfDNA Test Kits in Kidney Transplant Monitoring

Study shows iMDx test equivalent to NGS kits for dd-cfDNA measurement in kidney transplant patients, supporting future commercialization efforts. Results from a head-to-head comparison show iMDx's ...
Nasdaq

Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation

Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...
Labroots

Inexpensive, Fast Detection of Multiple Cancers From One Blood Sample

Scientists have created a novel method that could make the detection of multiple cancer types much easier. This method, ...
Business Wire

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera ...
Seeking Alpha

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...